Park Avenue Securities LLC Has $622,000 Stock Holdings in QIAGEN N.V. $QGEN

Park Avenue Securities LLC increased its position in QIAGEN N.V. (NYSE:QGEN) by 42.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,957 shares of the company’s stock after buying an additional 3,856 shares during the period. Park Avenue Securities LLC’s holdings in QIAGEN were worth $622,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Exchange Traded Concepts LLC grew its stake in shares of QIAGEN by 2.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock valued at $716,000 after buying an additional 395 shares during the period. SVB Wealth LLC acquired a new position in QIAGEN during the 1st quarter valued at about $31,000. Farther Finance Advisors LLC boosted its stake in QIAGEN by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares during the last quarter. Walleye Trading LLC boosted its stake in QIAGEN by 14.6% during the 1st quarter. Walleye Trading LLC now owns 7,367 shares of the company’s stock valued at $296,000 after purchasing an additional 936 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

QIAGEN Price Performance

Shares of NYSE QGEN opened at $43.85 on Monday. QIAGEN N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The stock’s 50 day moving average price is $47.90 and its 200-day moving average price is $45.11. The company has a market capitalization of $9.75 billion, a PE ratio of 25.91, a PEG ratio of 2.32 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

QIAGEN (NYSE:QGEN) last announced its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the previous year, the business earned $0.55 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on QGEN. Wall Street Zen downgraded QIAGEN from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 11th. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, June 26th. Cowen reiterated a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Barclays began coverage on QIAGEN in a research note on Tuesday, June 24th. They set an “overweight” rating and a $55.00 price target for the company. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.